# A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

> **NCT03823378** · PHASE2 · TERMINATED · sponsor: **AbbVie** · enrollment: 97 (actual)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** Elsubrutinib
- **DRUG:** Upadacitinib
- **DRUG:** Placebo for elsubrutinib
- **DRUG:** Placebo for upadacitinib

## Key facts

- **NCT ID:** NCT03823378
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-13
- **Primary completion:** 2020-09-09
- **Final completion:** 2020-09-09
- **Target enrollment:** 97 (ACTUAL)
- **Why stopped:** Study M16-763 was terminated early as the benefit of each treatment arm from the feeder study (Study M16-063) did not provide appreciable evidence of differentiated clinical effect to warrant further long-term continuation.
- **Last updated:** 2021-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03823378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03823378, "A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03823378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*